Higher frequency of aberrant crypt foci in rapid than slow acetylator inbred rats administered the colon carcinogen 3,2'-dimethyl-4-aminobiphenyl

Toxicology and Applied Pharmacology

Volumn 147, Issue 1, 1997, Pages 56-62

  Feng, Yi ^a   Fretland, Adrian J ^a   Rustan, Timothy D ^a   Jiang, Wen ^a   Becker, William K ^a   Hein, David W ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIMETHYLHYDRAZINE; 2',3 DIMETHYL 4 BIPHENYLAMINE; ACYLTRANSFERASE;

ACETYLATOR PHENOTYPE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; LIVER MICROSOME; NONHUMAN; RAT;

ANIMALIA; MAMMALIA;

EID: 0030725239     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8259     Document Type: Article

References (70)

1. Aragaki C. C., Greenland S., Probst-Hensch N., Haile R. W. Hierarchial modeling of gene-environment interactions: EstimatingNAT2*. Cancer Epid. Biomarkers Prev. 6:1997;307-314.
2. Bell D. A., Stephens E. A., Castranio T., Umbach D. M., Watson M., Deakin M., Elder J., Hendrickse C., Duncan H., Strange R. C. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1. Cancer Res. 55:1995;3537-3542.
3. Bird R. P. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: Preliminary findings. Cancer. Lett. 37:1987;147-151.
4. Bird R. P. Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett. 93:1995;55-71.
5. Boobis A. R., Lynch A. M., Murray S., del la Torre R., Solans A., Farre M., Segura J., Gooderham N. J., Davies D. S. CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res. 54:1994;89-94.
6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
7. Butler M. A., Guengerich F. P., Kadlubar F. F. Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylene-bis (2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P450 monooxygenases. Cancer Res. 49:1989a;25-31.
8. PA. Proc. Natl. Acad. Sci. USA. 86:1989b;7696-7700.
9. Caderni G., Giannini A., Lancioni L., Luceri C., Biggeri A., Dolara P. Characterization of aberrant crypt foci in carcinogen-treated rats: Association with intestinal carcinogenesis. Br. J. Cancer. 71:1995;763-769.
10. Cancer Facts and Figures, 1995, American Cancer Society, Atlanta, GA.
11. Cleveland J. C., Litvak S. F., Cole J. W. Identification of the route of action of the carcinogen 3,2′-dimethyl-4-aminobiphenyl in the induction of intestinal neoplasia. Cancer Res. 27:1967;708-714.
12. Corpet D. E., Stamp D., Medline A., Minkin S., Archer M. A., Bruce W. R. Promotion of colonic microadenoma growth in mice and rats fed cooked sugar or cooked casein and fat. Cancer Res. 50:1990;6955-6958.
13. Debiec-Rychter M., Land S. J., King C. M. Histological localization of messenger RNAs for rat acetyltransferases that acetylate serotonin and genotoxic arylamines. Cancer Res. 56:1996;1517-1525.
14. Doll M. A., Hein D. W. Cloning, sequencing and expression ofNAT1NAT2. Pharmacogenetics. 5:1995;247-251.
15. Dunning W. F., Curtis M. R., Madsen M. E. The induction of neoplasms in five strains of rats with acetylaminofluorene. Cancer Res. 7:1947;134-140.
16. Feng Y., Fretland A. J., Wagner R. J., Doll M. A., Becker W. K., Pretlow T. P., Hein D. W. Aberrant crypt formation in rapid and slow acetylator (NAT2. Proc. Am. Assoc. Cancer. 37:1996a;107.
17. Feng Y., Wagner R. J., Fretland A. J., Becker W. K., Cooley A. M., Pretlow T. P., Lee K. J., Hein D. W. Acetylator genotype (NAT2. Cancer Res. 56:1996b;527-531.
18. Fiala E. S., Weisburger J. H., Katayama S., Chandrasekaran V., Williams G. M. Effect of disulfiram on the carcinogenicity of 3,2′-dimethyl-4-aminobiphenyl in Syrian golden hamsters and rats. Carcinogenesis. 2:1981;965-969.
19. Flammang T. J., Kadlubar F. F. Acetyl coenzyme A-dependent metabolic activation of N-hydroxy-3,2′-dimethyl-4-aminobiphenyl and several carcinogenic N-hydroxyarylamines in relation to tissue and species differences, other acyl donors, and arylhydroxamic acid-dependent acetyltransferases. Carcinogenesis. 7:1986;919-926.
20. Flammang T. J., Westra J. G., Kadlubar F. F., Beland F. A. DNA adducts formed from the probable proximate carcinogen N-hydroxy-3,2′-dimethyl-4-aminobiphenyl by acid catalysis or S-acetyl coenzyme A-dependent enzymatic esterification. Carcinogenesis. 6:1985;251-258.
21. Guengerich F. P. Principles and Methods of Toxicology. 1989;Raven Press, New York.
22. Hein D. W. Acetylator genotype and arylamine-induced carcinogenesis. Biochem. Biophys. Acta. 948:1988;37-66.
23. Hein D. W., Doll M. A., Fretland A. J., Gray K., Deitz A. C., Feng Y., Jiang W., Rustan T. D., Satran S. L., Wilkie T. R. Sr. Rodent models of the human acetylation polymorphism: Comparisons of recombinant acetyltransferases. Mutat. Res. 376:1997;101-106.
24. Hein D. W., Doll M. A., Gray K., Rustan T. D., Ferguson R. J. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1NAT2NAT2. Cancer Res. 53:1993a;509-514.
25. Hein D. W., Doll M. A., Rustan T. D., Ferguson R. J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: Effects of 7 specificNAT2. Cancer Res. 55:1995;3531-3536.
26. Hein D. W., Doll M. A., Rustan T. D., Gray K., Feng Y., Ferguson R. J., Grant D. M. Metabolic activation and deactivation of arylamine carcinogens by recombinant humanNAT1NAT2. Carcinogenesis. 14:1993b;1633-1638.
27. Hein D. W., Rustan T. D., Bucher K. D., Furman E. J., Martin W. J. Extrahepatic expression of theN. J. Pharmacol. Exp. Ther. 258:1991a;232-236.
28. Hein D. W., Rustan T. D., Bucher K. D., Martin W. J., Furman E. J. Acetylator phenotype-dependent and -independent expression of arylamineN. Drug Metab. Dispos. 19:1991b;933-937.
29. Hein D. W., Rustan T. D., Ferguson R. J., Doll M. A., Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant NAT1 and NAT2 acetyltransferases. Arch. Toxicol. 68:1994;129-133.
30. Ilett K. F., David B. M., Dethon P., Castleden W. M., Kwa R. Acetylator phenotype in colorectal carcinoma. Cancer Res. 47:1987;1466-1469.
31. Jiang W., Doll M. A., Wilkie T., Satran S., Hein D. W. Expression ofNAT1NAT2. FASEB J. 10:1996;A456.
32. Jones R. F., Land S. J., King C. M. Recombinant rat and hamster N-acetyltransferases-1 and -2: Relative rates ofN. Carcinogenesis. 17:1996;1729-1733.
33. Juberg D. R., Bond J. T., Weber W. W. N. Pharmacogenetics. 1:1991;50-57.
34. Kadlubar F. F., Butler M. A., Kaderlik K. R., Chou H. C., Lang N. C. Polymorphisms for aromatic amine metabolism in humans - Relevance for human carcinogenesis. Environ. Health Perspect. 98:1992;69-74.
35. Konstantakos A. K., Siu I. M., Pretlow T. G., Stellato T. A., Pretlow T. P. Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer. Gastroenterology. 111:1996;772-777.
36. Ladero J. M., Gonzalez J. F., Benitez J., Vargas E., Fernandez M. J., Baki W., Diaz-Rubio M. Acetylator polymorphism in human colorectal carcinoma. Cancer Res. 51:1991;2098-2100.
37. Lam L. K., Zhang J. Reduction of aberrant crypt formation in the colon of CF1 mice by potential chemopreventive agents. Carcinogenesis. 12:1991;2311-2315.
38. Land S. J., Jones R. F., King C. M. Genetic analysis of two rat acetyltransferases. Carcinogenesis. 17:1996;1121-1126.
39. Lang N. P., Butler M. A., Massengell J., Lawson M., Stotts R. C., Hauer-Jensen M., Kadlubar F. F. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps. Cancer Epidemiol. Biomarkers Prev. 3:1994;675-682.
40. Lang N. P., Chu D. Z., Hunter C. F., Kendall D. C., Flammang T. J., Kadlubar F. F. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch. Surg. 121:1986;1259-1261.
41. Lang N. P., Kadlubar F. F. Aromatic and heterocyclic amine metabolism and phenotyping in humans. Glendhill B., Mauro F. New Horizons in Biological Dosimetry. 1991;34-47 Wiley-Liss, New York.
42. McLellan E. A., Bird R. P. Specificity study to evaluate induction of aberrant crypts in murine colons. Cancer Res. 48:1988a;6183-6186.
43. McLellan E. A., Bird R. P. Aberrant crypts: Potential preneoplastic lesions in the murine colon. Cancer Res. 48:1988b;6187-6192.
44. McLellan E. A., Medline A., Bird R. P. Dose response and proliferative characteristics of aberrant crypt foci: Putative preneoplastic lesions in rat colon. Carcinogenesis. 12:1991;2093-2098.
45. Minchin R. F., Reeves P. T., Teitel C. H., McManus M. E., Mojarrabi B., Ilett K. F., Kadlubar F. F. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed inCOS-1. Biochem. Biophys. Res. Commun. 185:1992;839-844.
46. Nussbaum M., Fiala E. S., Kulkarni B., El-Bayoumy E. S., Weisburger J. H. In vivo. Environ. Health Perspect. 49:1983;223-231.
47. Oda Y., Tanaka M., Nakanishi I. Relation between the occurrence of K-ras. Carcinogenesis. 15:1994;1365-1369.
48. Ogolla F., Ferguson R. J., Kirlin W. G., Trinidad A., Andrews A. F., Mpezo M., Hein D. W. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxyarylamine O-acetyltransferase in Syrian inbred hamster intestine and colon: Identity with the hepatic acetylation polymorphism. Drug Metab. Dispos. 18:1990;680-685.
49. Paulsen J. E., Steffensen I.-L., Namork E., Hein D. W., Alexander J. Effect of acetylator genotype on 3,2′-dimethyl-4-aminobiphenyl induced aberrant crypt foci in the colon of hamsters. Carcinogenesis. 17:1996;459-465.
50. Pretlow T. P. Alterations associated with early neoplasia in the colon. Pretlow T. G., Pretlow T. P. Biochemical and Molecular Aspects of Selected Cancers. 1994;93-141 Academic Press, San Diego.
51. Pretlow T. P., Barrow B. J., Ashton W. S., O'Riordan M. A., Pretlow T. G., Turcisek J. A., Stellato T. A. Aberrant crypts: Putative preneoplastic foci in human colonic mucosa. Cancer Res. 51:1991;1564-1567.
52. Pretlow T. P., O'Riordan M. A., Somich G. A., Amini S. B., Pretlow T. G. Aberrant crypts correlate with tumor incidence in F344 rats treated with azocymethane and phytate. Carcinogenesis. 13:1992;1509-1512.
53. Probst-Hensch N. M., Haile R. W., Ingles S. A., Longnecker M. P., Han C. Y., Lin B. K., Lee D. B., Sakamoto G. T., Franskl H. D., Lee E. R., Lin H. J. Acetylation polymorphism and prevalence of colorectal adenomas. Cancer Res. 55:1995;2017-2020.
54. Reddy B. S., Watanabe K. Effect of intestinal microfluora on 3,2′-dimethyl-4-aminobiphenyl-induced carcinogenesis in F344 rats. J. Natl. Cancer Inst. 61:1978;1269-1271.
55. Roberts-Thomson I. C., Ryan P., Khoo K. K., Hart W. J., McMichael A. J., Butler R. N. Diet, acetylator phenotype, and risk of colorectal neolasia. Lancet. 347:1996;1372-1374.
56. Rodriguez J. W., Kirlin W. G., Ferguson R. J., Doll M. A., Gray K., Rustan T. D., Lee M. E., Kemp K., Urso P., Hein D. W. Human acetylator genotype: Relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol. Arch. Toxicol. 67:1993;445-452.
57. Roncucci L., Medline A., Bruce W. R. Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol. Biomarkers Prev. 1:1991;57-60.
58. Rosenberg D. W., Mankowski D. C. Induction of cyp2e-1 protein in mouse colon. Carcinogenesis. 15:1994;73-78.
59. Shirai T., Nakamura A., Fukushima S., Yamamoto A., Tada M., Ito N. Different carcinogenic responses in a variety of organs, including the prostate, of five different rat stains given 3,2′-dimethyl-4-aminobiphenyl. Carcinogenesis. 11:1990;793-797.
60. Siu I.-M., Pretlow T. G., Amini S. B., Pretlow T. P. Identification of dysplasia in human colonic aberrant crypt foci. Am. J. Path. 150:1997;1805-1813.
61. Sohn O. S., Ishizaki H., Yang C. S., Fiala E. S. Metabolism of azocymethane, methylazocymethanol andN. Carcinogenesis. 12:1991;127-131.
62. Spjut H. J., Noall M. W. Experimental induction of tumors of the large bowel of rats: A review of the experience with 3,2′-dimethyl-4-aminobiphenyl. Cancer. 28:1971;29-37.
63. Steffensen I.-L., Paulsen J. E., Alexander J. Unexpected antagonistic action of 3,2′-dimethyl-4-aminobiphenyl on aberrant crypt induction by 1,2-dimethylhydrazine or azomethane in rat colon. Carcinogenesis. 12:1995;2981-2988.
64. Tudek B., Bird R. P., Bruce W. R. Foci of aberrant crypts in the colons of mice and rats exposed to carcinogens associated with food. Cancer Res. 49:1989;1236-1240.
65. Turesky R. H., Lang N. P., Butler M. A., Teitel C. H., Kadlubar F. F. Metabolic activation of carcinogenic heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 12:1991;1839-1845.
66. Vatsis K. P., Weber W. W., Bell D. A., Dupret J. M., Evans D. A. P., Grant D. M., Hein D. W., Lin H. J., Meyer U. A., Relling M. V., Sim E., Suzuki T., Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics. 5:1995;1-17.
67. Walpole A. L., Williams M. H. C., Roberts D. C. The carcinogenic action of 4-aminobiphenyl and 3,2′dimethyl-4-aminobiphenyl. Br. J. Indust. Med. 9:1952;255-263.
68. Westra J. G., Flammang T. J., Fullerton N. F., Beland F. A., Weis C. C., Kadlubar F. F. Formation of DNA adductsin vivo. Carcinogenesis. 6:1985;37-41.
69. Wick M. J., Hanna P. E. Bioactivation of N-arylhydroxamic acids by rat hepatic N-acetyltransferase: Detection of multiple enzyme forms by mechanism-based inactivation. Biochem. Pharmacol. 39:1990;991-1003.
70. Williams G. M., Chandrasekaran V., Katayama S., Weisburger J. H. Carcinogenicity of 3-methyl-2-naphthylamine and 3,2′-dimethyl-4-aminobiphenyl to the bladder and gastrointestinal tract of the Syrian golden hamster with atypical proliferative enteritis. J. Natl. Cancer Inst. 67:1981;481-488.